Current Oncology Reports

, Volume 4, Issue 5, pp 415–423

Changing role and decreasing size: Current trends in radiotherapy for hodgkin’s disease

  • Joachim Yahalom

DOI: 10.1007/s11912-002-0036-9

Cite this article as:
Yahalom, J. Curr Oncol Rep (2002) 4: 415. doi:10.1007/s11912-002-0036-9


Radiotherapy, the first cancer treatment modality that offered cure, is still considered to be the most effective “single agent” in treating Hodgkin’s disease (HD). Yet, the role of radiotherapy in HD has changed dramatically with the advent of effective combination chemotherapy and the rising concern of long-term complications associated with successful treatment of HD. The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design.

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Joachim Yahalom
    • 1
  1. 1.Department of Radiation Oncology, Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell UniversityNew YorkUSA